Home » Agenda » Day 1

Day 1

5th PATIENT CENTRICITY & COLLABORATION WORLD CONGRESS 2024 EUROPE

Patient empowerment and understanding to inspire and create a meaningful impact.

Copthorne Tara Hotel London Kensington, London, UK

Day 1 - Monday 26th February 2024

Emma Sutcliffe, Global Patient Officer, Ipsen Biopharma

 

TRENDS & STRATEGIES IN INTEGRATING PATIENT VOICE

  • The value of engaging and communicating with the patient in every part of the clinical research process
  • Examining the right approach for patient and industry to positively impact healthcare costs and patient outcomes through patient engagement
  • How can patient expertise create significant value to the industry?
  • What are the best practices and strategies to guarantee that patient centricity is at the forefront of pharma?

Moderator:
TBC
Panelists:

  • Empowerment, experience, evidence – the impact of the patient voice
  • Engagement delivers value as a triple win – for patients, for pharma, for society
  • Ensuring voice to value in the ‘Patient 3.0’ era

Emma Sutcliffe, Global Patient Officer, Ipsen Biopharma

  • Many biotech/pharmaceutical companies are talking about ”Patient Centricity”, but how can a company actually operate in a patient-centric way to create meaningful value?
  • Learn best practices to transition from being product centered to patient centered
  • Discuss strategies to embed patient centricity throughout your organization.

Christel Paganoni-Bruijns, Global Head Community Engagement, Swedish Orphan Biovitrum AB

  • Patient Centricity requires new mindsets, relationships – and structures, company-wide.
  • No stage of development, from discovery through delivery, gets a pass.
  • No company function continues as before.
  • Company culture changes, too.
  • This isn’t easy but the results are worth the journey: to improve outcomes for patients and business performance alike.
  • If Patient Centricity is a fad, then it’s a failure. It should be the new way of doing business.

Bronwyn Lewis, Global Head of Patient Engagement, Boehringer Ingelheim International GmbH

  • Sharing insights into a live real-world example of this type of partnership
  • Explaining the roles and responsibilities in achieving a positive outcome
  • Providing key learnings to the evolving process
  • Supplying the audience with guiding principles for future partnerships

 

  • Learn about the latest technologies that can improve the efficiency and effectiveness of clinical trial design, addressing issues like increasing complexity
  • Discover the principles and best practices for clinical trial design that can increase the likelihood of success, through a combination of literature analysis and practical experience
  • Examine the challenges faced by patients during clinical trials and learn about potential solutions that can reduce the burden and increase the benefits for patients
  • Understand where patient centricity can advance the interests shared by industry and the patient community
  • Consider how focused goals and programs can strengthen research and development, commercialization and access
  • Focus on opportunities to integrate patients, caregivers, consumers and advocates’ key concerns and insights into company plans and decision making
  • Discuss applications of this targeted approach to your patient centricity goals and programs

Moderator:


Panellist:

  • The international perspective on what people with type 1 diabetes want from industry, according to international region
  • The Nobel Prize winning discovery of insulin in 1921 and how that legacy defines what people living with type 1 now want from industry
  • Type 1 diabetes patient priorities for the pharmaceutical industry and medical device industry
  • The rise of citizen science and how that changes the relationship that type 1 diabetes patient advocates want to be engaged with in industry research and development
  • A framework for patient engagement

Hilary Nathan, Policy, Communications & Community Engagement Director, JDRF

  • Education of the process of clinical trials
  • Listen to the Patient needs and help them to understand what the focus of the trial is.
  • Understanding Pharmaceutical costs of trials and research
  • Dealing with an illness with multiple organ involvement.
  • Rare Disease
  • Why there is a need for Patient involvement in publications framework
  • What is the framework?
  • How did we co-create the framework with cross-functional team and patients – the methodology
  • Ongoing implementation, feedback loops early applications and expected impact

Ana Marija Gjurovic, Global Head Patient Engagement, AstraZeneca

  • Contributions that advocacy groups can make to clinical trial development
  • The importance of knowing the people, their disease, and its burdens
  • Successful collaborations are a win for all
  • Patient perception and usability of drug products is critical for efficacy of prescribed treatments.
  • Drug products should be designed to meet the specific needs of the target patient populations.
  • A patient centric drug product design approach is critical to support optimal therapeutic outcomes for drug products.
  • Roll out of digital technology will support the implementation of a patient centric mindset for drug product design.
  • Case-studies for drug products developed via patient centric drug product design
  • What is high realistic simulation?
  • How we can simulate a clinical trial protocol.
  • Role of patients and professionals in simulation.
  • Return on the investment and return on the engagement

Begoña Nafría Escalera, Coordinator of eYPAGnet, Hospital Sant Joan de Déu

  • Integration of the patient perspective into the development process
  • Challenges and strategies for improving study protocols
  • Streamline your clinical trial process to drive enrollment
  • Contributions that advocacy groups can make to clinical trial development
  • The importance of knowing the people, their disease, and its burdens
  • Successful collaborations are a win for all

Moderator:


Panellist:

Scroll to Top